The model effectively stratified patients into high-risk (5-year OS: 49.3%) and low-risk (86.0%) groups.<h4>Conclusion</h4>The introduction of BV has significantly improved real-world survival in ALK+ ALCL. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.